 Home > Active Ingredient News > Antitumor Therapy > ESMO Open: Efficacy of avelumab combined with axitinib vs sunitinib for advanced sarcomatoid renal cell carcinoma

ESMO Open: Efficacy of avelumab combined with axitinib vs sunitinib for advanced sarcomatoid renal cell carcinoma

 Last Update: 2021-05-08
 Source: Internet
 Author: User

Tags

al hco3 3

3 8 simplified

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Most of the histological type of renal cell carcinoma (RCC) is clear cell carcinoma, and a small part may be a sarcoma-like type, that is, sarcomatoid renal cell carcinoma (sRCC).

This article aims to evaluate the efficacy of avelumab combined with axitinib or sunitinib in untreated patients with advanced sRCC .

This article aims to evaluate the efficacy of avelumab combined with axitinib or sunitinib in untreated advanced sRCC patients with sunitinib

The JAVELIN Renal 101 study is a randomized, open-label, multi-center phase III clinical trial.

Comparison of the prognosis of the two groups of patients

A total of 108 sRCC patients were included in this post-hoc analysis: 47 were treated with avelumab + axitinib, and 61 were treated with avelumab + sunitinib.

Compared with sunitinib group, Asif for progression-free survival in patients with non-Nepalese groups and objective response rate were significantly increased

Related gene expression analysis

Analysis of related gene expression in sRCC patients showed that fibroblasts and regulatory T cells related to cancer, CD274 and CD8A expression, and tumor gene pathways classified by Atlas m3 of the oncogenome were significantly richer.

The subgroup analysis of the JAVELIN Renal 101 trial showed that the efficacy and prognosis of sRCC patients treated with avelumab combined with axitinib was significantly higher than that of patients treated with avelumab combined with sunitinib .

The efficacy and prognosis of sRCC patients treated with avelumab and axitinib were significantly improved compared with patients treated with avelumab and sunitinib Significantly improved

Original source:

Choueiri TK, Larkin J, Pal S et al.

org/10.
1016/j.
esmoop.
2021.
100101" target="_blank" rel="noopener">Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.